Cancer Immunotherapy: Beyond Checkpoint Blockade.
Cancer Immunotherapy: Beyond Checkpoint Blockade.
复制标题
DOI：
10.1146/annurev-cancerbio-030518-055552
复制
发表时间：
2019-03
影响因子：
7.7
通讯作者：
Dougan, Stephanie K.
中科院分区：
文献类型：
--
作者：
Dougan, Michael;Dranoff, Glenn;Dougan, Stephanie K.
关键词：
阻断免疫检查点受体或其配体的抗体已经彻底改变了各种恶性肿瘤的治疗。许多肿瘤被适应性免疫识别，但这些适应性反应可以被肿瘤内的免疫抑制机制抑制，通常是通过目前靶向检查点以外的途径。因此，只有少数癌症患者对目前的免疫疗法产生了持久的反应。多种新方法努力扩大免疫治疗的范围。这些可能包括靶向替代免疫检查点。然而，许多调查策略超越了检查站封锁。这些包括绕过内源性免疫的细胞疗法和使用疫苗、佐剂和与细胞毒性疗法的组合刺激新的适应性抗肿瘤应答的努力，以及抑制先天免疫抑制和调节肿瘤微环境内代谢的策略。未来免疫治疗的挑战将是选择合理的策略，以克服来自无数可能靶点的有效抗肿瘤反应的障碍。
Blocking antibodies to the immune checkpoint receptors or their ligands have revolutionized the treatment of diverse malignancies. Many tumors are recognized by adaptive immunity, but these adaptive responses can be inhibited by immunosuppressive mechanisms within the tumor, often through pathways outside of the currently targeted checkpoints. For this reason, only a minority of cancer patients achieve durable responses to current immunotherapies. Multiple novel approaches strive to expand immunotherapy’s reach. These may include targeting alternative immune checkpoints. However, many investigational strategies look beyond checkpoint blockade. These include cellular therapies to bypass endogenous immunity and efforts to stimulate new adaptive antitumor responses using vaccines, adjuvants, and combinations with cytotoxic therapy, as well as strategies to inhibit innate immune suppression and modulate metabolism within the tumor microenvironment. The challenge for immunotherapy going forward will be to select rational strategies for overcoming barriers to effective antitumor responses from the myriad possible targets.
登录
查看更多内容
影响因子：
8.8
作者：
Corrales L;Glickman LH;McWhirter SM;Kanne DB;Sivick KE;Katibah GE;Woo SR;Lemmens E;Banda T;Leong JJ;Metchette K;Dubensky TW Jr;Gajewski TF
通讯作者：
Gajewski TF
影响因子：
82.9
作者：
Chesi M;Mirza NN;Garbitt VM;Sharik ME;Dueck AC;Asmann YW;Akhmetzyanova I;Kosiorek HE;Calcinotto A;Riggs DL;Keane N;Ahmann GJ;Morrison KM;Fonseca R;Lacy MQ;Dingli D;Kumar SK;Ailawadhi S;Dispenzieri A;Buadi F;Gertz MA;Reeder CB;Lin Y;Chanan-Khan AA;Stewart AK;Fooksman D;Bergsagel PL
通讯作者：
Bergsagel PL
DOI：
10.1084/jem.20050915
发表时间：
2005-12-19
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Casares N;Pequignot MO;Tesniere A;Ghiringhelli F;Roux S;Chaput N;Schmitt E;Hamai A;Hervas-Stubbs S;Obeid M;Coutant F;Métivier D;Pichard E;Aucouturier P;Pierron G;Garrido C;Zitvogel L;Kroemer G
通讯作者：
Kroemer G
可注射冷冻凝胶的全细胞癌疫苗。
影响因子：
16.6
作者：
Bencherif SA;Warren Sands R;Ali OA;Li WA;Lewin SA;Braschler TM;Shih TY;Verbeke CS;Bhatta D;Dranoff G;Mooney DJ
通讯作者：
Mooney DJ
影响因子：
11.2
作者：
Cekic C;Day YJ;Sag D;Linden J
通讯作者：
Linden J